AUTHORS
Zhuoxin Wen, Bin Xu2, Fankai Meng3, Andie Fu4, Yuling Wan5, Yi Zhu6, Shiyuan Zhang7, Jinhuan Xu8, Jia Wei, MD, PhD9, Donghua Zhang, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology10
AFFILIATIONS
1 Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
2 Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
3 Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
4 Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
5 Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
6 Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
7 Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
8 Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
9 Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
10 Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
ABSTRACT
Background
Delayed platelet engraftment following allo-HSCT remains a significant clinical challenge, leading to prolonged platelet transfusion dependence and increased risks of bleeding, infectious complications, and adverse clinical outcomes. Romiplostim, a thrombopoietin receptor agonist (TPO-RA), stimulates megakaryopoiesis and platelet production through activation of the thrombopoietin receptor (c-Mpl). Although widely used for immune thrombocytopenia and chemotherapy-induced thrombocytopenia, whether early prophylactic romiplostim administration can enhance platelet recovery after allo-HSCT without compromising transplant outcomes remains unclear.
Methods
We conducted a retrospective cohort study of patients undergoing allo-HSCT at our institution. Patients receiving prophylactic romiplostim were compared with a control cohort using propensity score matching. Baseline characteristics, including age, disease characteristics, conditioning regimen, donor type, CD34? cell dose, and stem cell source, were balanced after matching.Patients in the romiplostim group received subcutaneous romiplostim at 4 μg/kg weekly beginning on day +3 after allo-HSCT until platelet recovery ≥75×10?/L. The primary endpoint was time to platelet recovery ≥50×10?/L. Secondary endpoints included platelet and neutrophil engraftment, platelet transfusion requirement, hospitalization duration, GVHD, TA-TMA, OS, and PFS. Time-to-event outcomes were evaluated using Kaplan–Meier analysis and log-rank testing.
Results
After screening, a total of 103 eligible patients were included in the initial cohort, including 54 patients who received prophylactic romiplostim and 49 patients who received standard supportive care alone. Following 1:1 propensity score matching, 66 patients (33 pairs) were included in the final analysis. The median time to platelet recovery ≥50×10?/L was significantly shorter in patients receiving prophylactic romiplostim compared with controls (15 and 17.5 days, respectively; P=0.020). Kaplan–Meier analysis demonstrated a higher cumulative probability of platelet recovery ≥50×10?/L in the romiplostim group (log-rank P=0.047). Platelet engraftment occurred earlier among patients receiving romiplostim, with median recovery times of 12 days compared with 14 days in the control group (P=0.012).Neutrophil engraftment was comparable between groups, with median recovery times of 13 days in the romiplostim group and 14 days in the control group (P=0.102), suggesting a preferential effect of romiplostim on platelet recovery rather than neutrophil recovery. The romiplostim group required fewer platelet transfusions, with a median requirement of 5 units compared with 6 units in controls (P=0.066). The duration of hospitalization was comparable between groups, with median durations of 32 and 35 days, respectively (P=0.264).Regarding safety outcomes, grade II–IV acute GVHD occurred at similar rates in the romiplostim and control cohorts (15.2% and 21.2%; P=0.751). Similarly, no significant differences were observed in grade III–IV acute GVHD, chronic GVHD, or TA-TMA incidence.No significant differences were observed in overall survival (OS; log-rank P=0.20) or progression-free survival (PFS; log-rank P=0.50).Exploratory subgroup analyses showed consistent benefits among PBSCs recipients (n=58; P=0.029 for time to platelet recovery ≥50×10?/L and P=0.0026 for platelet engraftment) and acute leukemia patients (n=49; P=0.017 and P=0.008, respectively).
Conclusion
Early prophylactic romiplostim after allo-HSCT was associated with faster platelet recovery and earlier platelet engraftment without increased GVHD, TA-TMA, or adverse survival outcomes. These findings suggest that romiplostim may represent a promising supportive therapy for improving post-transplant platelet recovery.
DISCLOSURES
Donghua Zhang, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology: No relevant conflicts of interest to declare.